German science and technology company selling life-science lab tools (MilliporeSigma), specialty pharmaceuticals and electronic materials for chipmaking.
German science and technology company selling life-science lab tools (MilliporeSigma), specialty pharmaceuticals and electronic materials for chipmaking.
Life Science, selling lab supplies and the filters and media drugmakers need to make biologic drugs, is the biggest part, with recurring consumables rather than machines. Healthcare and electronic materials are the other two. The Merck family keeps control through a holding company. It bought Sigma-Aldrich in 2015 and Versum Materials in 2019.
In one line: Owns MilliporeSigma; unrelated to US-listed Merck & Co.
Moat: narrow (switching costs, IP / patents, customer qualification). Lab reagents/bioprocessing tools are validated into customer workflows, and electronic materials require fab qualification.
Headquarters: Darmstadt, Germany · Founded: 1668 · Employees: 62,461
Size Merck KGaA (MRK.DE) is a Germany Health Care company (Pharmaceuticals: Major) with a market value of $71.3B, the 8th largest of 198 Germany companies the cockpit tracks. Shares closed at €149.50 on 18 Nov 2026.
Performance Over six months the shares gained 16.5%, against +11.2% for the median peer and -0.9% for the Germany market (cap-weighted) — 10th highest of 21 in its peer set.
Growth Revenue grew 0.8% over the last twelve months (peer median +8.6%); the operating margin is 19.4% (peer median 25.3%).
Valuation It trades at 17.4× forward earnings against a peer median of 16.9× (9th most expensive of 21).
Price implies For today's price to make sense, revenue must grow about 7% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is +4 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 0.6 points above its cost of capital (6.7% WACC).
Credit Merck KGaA has 10 bonds outstanding ($7.08B), rated A by the agencies and trading like AA+ at a weighted spread of 67 bp.
Next results Next results expected around 4 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | €21.4B | €21.1B | €21.2B | €21.0B | €22.2B |
| Revenue growth | — | 0% | +1% | -6% | — |
| Gross profit | €12.6B | €11.9B | €11.9B | €11.7B | €12.8B |
| EBITDA | €7.10B | €5.95B | €6.17B | €5.83B | €6.79B |
| Net income | €1.92B | €2.61B | €2.78B | €2.82B | €3.33B |
| Free cash flow | €3.00B | €2.35B | €2.88B | €1.98B | €2.73B |
| Capital expenditure | €3.67B | €3.56B | €4.43B | €4.52B | €2.88B |
| Total debt | €12.0B | €12.0B | €10.3B | €9.94B | €10.4B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Merck KGaA MRK.DE | $71.3B | +16% | +1% | 19% | 17.4× | 7.4% |
| Thermo Fisher Scientific TMO | $257B | +53% | +8% | 19% | 25.7× | 21.3% |
| Danaher DHR | $161B | +34% | +6% | 21% | 25.1× | 20.8% |
| Bayer BAYN.DE | $60.3B | +48% | 0% | 13% | 12.3× | n/a |
| Shin-etsu Chemical 4063.T | $67.9B | -22% | +5% | 25% | 17.7× | 9.9% |
| Sartorius SRT.DE | $19.9B | +26% | +4% | 18% | 43.0× | 25.6% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | MRK.DE | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +2.1% | +5.0% | 8th lowest of 21 |
| 6-month return | +16.5% | +11.2% | 10th highest of 21 |
| Distance from 52-week high | -4.3% | -7.4% | 6th highest of 21 |
| Revenue growth (TTM) | +0.8% | +8.6% | 3rd lowest of 21 |
| Operating margin | 19.4% | 25.3% | 8th lowest of 21 |
| Forward P/E | 17.4× | 16.9× | 9th most expensive of 21 |
| Growth the price implies (Req g, 7 yrs) | 7.4% | 5.2% | 8th most demanding of 20 |
| Growth delivered (Del g) | +3.8% | +7.1% | 8th lowest of 20 |
| Hurdle (Req g minus delivered) | +3.7 pp | -4.8 pp | 7th most demanding of 20 |
| ROIC minus cost of capital | +0.6 pp | +4.8 pp | 5th lowest of 21 |
| EV / EBITDA | 10.4× | 13.8× | 8th cheapest of 19 |
| Net debt / EBITDA | 1.2× | 1.8× | 8th least indebted of 19 |
| Bond spread | 67 bp | 84 bp | 2nd tightest of 14 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Merck KGaA MRK.DE | Germany | $71.3B | +16% | +1% | 19% | 17.4× | 7.4% | +3.8% |
| Takeda Pharmaceutical 4502.T | Japan | $69.8B | +30% | +6% | 18% | 51.0× | 3.7% | +7.1% |
| Chugai Pharmaceutical 4519.T | Japan | $75.2B | -8% | +17% | 50% | 23.7× | 5.0% | +9.8% |
| WuXi AppTec 603259.SS | China | $64.2B | +40% | +32% | 43% | 17.0× | 7.2% | +22.3% |
| Bayer BAYN.DE | Germany | $60.3B | +48% | 0% | 13% | 12.3× | n/a | n/a |
| Regeneron Pharmaceuticals REGN | United States | $97.8B | +46% | +19% | 30% | 11.8× | -1.1% | +11.0% |
| GSK GSK.L | United Kingdom | $97.9B | -3% | +4% | 25% | 10.4× | -0.1% | -0.9% |
| Galderma GALD.SW | Switzerland | $51.9B | +18% | +16% | 19% | 45.7× | 18.0% | +6.4% |
| Sun Pharmaceutical Industries SUNPHARMA.NS | India | $48.0B | -1% | +12% | 23% | 36.0× | 28.7% | +11.7% |
| Jiangsu Hengrui Pharmaceuticals 600276.SS | China | $45.7B | -13% | +6% | 27% | 33.4× | 13.4% | +2.7% |
| BeOne Medicines 688235.SS | China | $45.5B | +9% | +25% | 18% | 59.7× | 19.1% | +79.3% |
| Sanofi SAN.PA | France | $114B | +13% | +15% | 27% | 9.7× | -4.8% | +3.9% |
| Bristol Myers Squibb BMY | United States | $122B | +3% | +4% | 33% | 9.2× | -13.1% | +2.5% |
| Sandoz SDZ.SW | Switzerland | $41.7B | +26% | +1% | 15% | 24.5× | 7.5% | +0.4% |
| Otsuka Hldgs 4578.T | Japan | $39.9B | +9% | +11% | 18% | 16.8× | 1.6% | +11.7% |
| Haleon HLN.L | United Kingdom | $39.6B | 0% | +1% | 23% | 16.4× | 5.2% | +2.2% |
| Royalty Pharma RPRX | United States | $39.4B | +29% | +11% | 66% | 11.5× | 10.8% | +2.3% |
| Vertex Pharmaceuticals VRTX | United States | $136B | +25% | +11% | 35% | 28.5× | 6.2% | +14.2% |
| Biogen BIIB | United States | $37.2B | +34% | +2% | 17% | 17.1× | 10.1% | -5.1% |
| Zoetis ZTS | United States | $34.8B | +7% | +1% | 37% | 13.8× | -2.9% | +7.2% |
| Pfizer PFE | United States | $160B | +9% | +1% | 26% | 9.9× | -4.3% | +8.5% |
Merck KGaA has 10 bonds outstanding with $7.08B face value. The agencies rate it A; its bonds trade like AA+. Weighted yield 4.07%, a spread of 67 bp over government bonds.